Parkinson's disease drug market to reach $3.75 billion in 2015, says Visiongain

The market for Parkinson's disease drugs will reach a value of $3.754 billion in 2015. This decade, new products, including adenosine receptor antagonists, will benefit the Parkinson's treatment market and stimulate growth of overall revenue, says a new report from business information provider Visiongain.

The market for Parkinson's disease drugs generated $3.35 billion in 2010, according to the report, titled Parkinson's Disease: World Drug Market 2011-2021. The Parkinson's treatment market has potential to expand. In 2011 there are more than 300 late-stage trials of Parkinson's drugs in progress.

Parkinson's disease is a prominent neurodegenerative disorder. Though it is primarily a movement disorder, with symptoms including tremor and bradykinesia, it often causes cognitive effects including dementia and psychosis. Because Parkinson's affects mostly the elderly, the aging of the world population will result in its prevalence increasing, giving opportunities to the pharmaceutical industry.